Qnomx offers an AI‑driven software layer for oncology diagnostic labs that automates evidence gathering, database cross‑referencing, and report generation for somatic NGS cancer tests.
Funding
Funding not disclosed
Founders
Product
Problem
Oncology diagnostic laboratories spend a large portion of expert time manually gathering evidence, cross‑referencing databases, and formatting reports for somatic NGS cancer tests, which limits throughput and delays results.
Solution
Qnomx provides an AI‑driven software layer that sits between variant filtering and clinical sign‑off. It automatically aggregates evidence from curated sources such as OncoKB, COSMIC, and ClinVar, applies consistent clinical classification frameworks, and generates structured variant‑level interpretations with confidence scores and source attribution. These interpretations are then transformed into configurable, multilingual clinician‑ready reports that align with each lab’s reporting standards and include trial references where applicable. Experts retain full review and approval control, while the platform reduces repetitive workload by up to 85%, enabling labs to scale case volumes without adding staff and to deliver reports faster.
Target Audience
Primary customers are oncology diagnostic laboratories and molecular pathology teams that perform somatic NGS testing and need to increase interpretation capacity while maintaining expert oversight.
Features
- Automated evidence retrieval and synthesis from industry‑standard databases (OncoKB, COSMIC, ClinVar) and literature.
- Consistent application of clinical classification frameworks with displayed reasoning, confidence levels, and source attribution.
- Structured variant‑level interpretation view that supports efficient expert review and reduces lookup redundancy.
- Configurable report generation respecting lab‑specific content standards, layout, and multilingual output.
- Integrated review and sign‑off workflow allowing experts to edit and approve reports before release.
- Seamless integration into existing tertiary NGS pipelines without altering validated upstream processes.
- GDPR‑compliant data handling with ISO 27001 certification and EU/Swiss data residency options.